Paraoxonase 1 Polymorphisms Within a Mississippi USA Population as Possible Biomarkers of Enzyme Activities Associated With Disease Susceptibility

[1]  R. Leis,et al.  Paraoxonase 1 activities and genetic variation in childhood obesity , 2013, British Journal of Nutrition.

[2]  S. Rizvi,et al.  Plasma protein hydroperoxides during aging in humans: correlation with paraoxonase 1 (PON1) arylesterase activity and plasma total thiols. , 2013, Archives of medical research.

[3]  S. Rizvi,et al.  Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: correlation with susceptibility of LDL oxidation. , 2012, Archives of medical research.

[4]  G. Jarvik,et al.  Additional Common Polymorphisms in the PON Gene Cluster Predict PON1 Activity but Not Vascular Disease , 2012, Journal of lipids.

[5]  E. Jansen,et al.  Long term stability of paraoxonase-1 and high-density lipoprotein in human serum , 2012, Lipids in Health and Disease.

[6]  Dan S. Tawfik,et al.  Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1. , 2012, Journal of molecular biology.

[7]  R. Wills,et al.  Relationship of human paraoxonase-1 serum activity and genotype with atherosclerosis in individuals from the Deep South , 2011, Pharmacogenetics and genomics.

[8]  L. Costa,et al.  Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. , 2011, Biochemical pharmacology.

[9]  Y. Hussein,et al.  Association of L55M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance , 2011, Molecular and Cellular Biochemistry.

[10]  D. Draganov.  Lactonases with organophosphatase activity: structural and evolutionary perspectives. , 2010, Chemico-biological interactions.

[11]  Byoung-Soo Shin.  Paraoxonase Gene Polymorphism in South-western Korean Population , 2009, Journal of Korean medical science.

[12]  K. Davis,et al.  Racial Differences in Paraoxonase-1 (PON1): A Factor in the Health of Southerners? , 2009, Environmental health perspectives.

[13]  L. Almasy,et al.  Determinants of variation in human serum paraoxonase activity , 2009, Heredity.

[14]  H. Uzun,et al.  Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population , 2008, Clinical and Experimental Medicine.

[15]  D. Jacobs,et al.  Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) study. , 2008, Clinical chemistry.

[16]  H. Berrougui,et al.  Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging , 2007, Experimental Gerontology.

[17]  T. Sura,et al.  Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects. , 2007, Chemico-biological interactions.

[18]  P. Peeters,et al.  Genetic and environmental determinants of the PON‐1 phenotype , 2007, European journal of clinical investigation.

[19]  B. Quintanilla-Vega,et al.  Genetic polymorphisms and activity of PON1 in a Mexican population. , 2005, Toxicology and applied pharmacology.

[20]  M. Mackness,et al.  Paraoxonase 1 status in the Thai population , 2005, Journal of Human Genetics.

[21]  L. Costa,et al.  Modulation of paraoxonase (PON1) activity. , 2005, Biochemical pharmacology.

[22]  J. Kastelein,et al.  Variation at the paraoxonase gene locus contributes to carotid arterial wall thickness in subjects with familial hypercholesterolemia. , 2005, Clinical biochemistry.

[23]  E. Boerwinkle,et al.  Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community. The Bogalusa Heart Study. , 2004, Atherosclerosis.

[24]  S. Deakin,et al.  Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. , 2004, Clinical science.

[25]  M. Mackness,et al.  Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? , 2004, Free radical biology & medicine.

[26]  M. Aviram.  Introduction to the serial review on paraoxonases, oxidative stress, and cardiovascular diseases. , 2004, Free radical biology & medicine.

[27]  T. Isbir,et al.  Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non‐insulin dependent diabetes mellitus , 2004, Cell biochemistry and function.

[28]  C. Franceschi,et al.  Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis , 2004, Experimental Gerontology.

[29]  J. Ramires,et al.  PON1 M/L55 mutation protects high-risk patients against coronary artery disease. , 2004, International journal of cardiology.

[30]  J. Danesh,et al.  Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies , 2004, The Lancet.

[31]  T. Fulop,et al.  Study of factors influencing the decreased HDL associated PON1 activity with aging , 2004, Experimental Gerontology.

[32]  Jia Chen,et al.  Increased influence of genetic variation on PON1 activity in neonates. , 2003, Environmental health perspectives.

[33]  K. Allebrandt,et al.  Variability of the paraoxonase gene (PON1) in Euro- and Afro-Brazilians. , 2002, Toxicology and applied pharmacology.

[34]  A. Khalil,et al.  Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[35]  G. Jarvik,et al.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. , 2001, American journal of human genetics.

[36]  P. Durrington,et al.  Paraoxonase and Atherosclerosis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[37]  C Watson,et al.  Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[38]  G. Schellenberg,et al.  Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[39]  M. Aviram,et al.  Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. , 2000, Circulation.

[40]  I. Leviev,et al.  Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[41]  H. Hendriks,et al.  Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. , 1999, Atherosclerosis.

[42]  C. Furlong,et al.  Determination of paraoxonase (PON1) status requires more than genotyping. , 1999, Pharmacogenetics.

[43]  R. Walker,et al.  Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[44]  B. La Du,et al.  Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[45]  J. Miller,et al.  Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. , 1998, Atherosclerosis.

[46]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[47]  O. Lockridge,et al.  Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Adkins,et al.  Studies on human serum paraoxonase/arylesterase. , 1993, Chemico-biological interactions.

[49]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[50]  J. Chambers,et al.  Time course of inhibition of acetylcholinesterase and aliesterases following parathion and paraoxon exposures in rats. , 1990, Toxicology and applied pharmacology.

[51]  A. Mazur.  An enzyme in animal tissues capable of hydrolysing the phosphorus-fluorine bond of alkyl fluorophosphates. , 1946, The Journal of biological chemistry.

[52]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[53]  A. Navarro,et al.  The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. , 2009, Clinical biochemistry.

[54]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[55]  W. Aldridge.  Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. , 1953, The Biochemical journal.

[56]  W. Aldridge.  Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. , 1953, The Biochemical journal.